Rise and shine, everyone, another busy day is on the way. We could tell because our own early warning signal — our shortest person — raced faster than usual for the bus to the local schoolhouse. And things have hardly calmed down because of our growing to-do list. No doubt, you may relate. So let us join together and quaff delicious cups of stimulation. Nothing like a shared ritual, yes? Meanwhile, here are some tidbits. Have a great day and keep in touch …

There is an increased chance that large index funds will join the move toward changing the Mylan board, writes Sanford Bernstein analyst Ronny Gal. Four pension funds are pushing for change and one proxy firm advised shareholders to oust 10 directors, including the chief executive officer and non-corporate chair. He noted some of the large indexers are “getting more active on governance,” and “Mylan has been a standout of poor governance.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy